Target Details
| UniProt AC | P42345 |
|---|---|
| Gene Symbol | MTOR |
| Protein Name | Serine/threonine-protein kinase mTOR |
| Organism | Homo sapiens |
| Entry Name | |
| Organism Category | Human |
| Pfam Domains | PF02259 (FAT) PF02260 (FATC) PF08771 (FRB_dom) PF23593 (HEAT_ATR) PF11865 (mTOR_dom) PF00454 (PI3_PI4_kinase) |
Summary
- Multi-target molecules 2,517
- Clinical molecules 193
- Avg pChEMBL 7.75
KEGG Pathways (53)
- AMPK signaling pathway
- Acute myeloid leukemia
- Adipocytokine signaling pathway
- Alzheimer disease
- Amyotrophic lateral sclerosis
- Apelin signaling pathway
- Autophagy - animal
- Autophagy - other
- Breast cancer
- Cellular senescence
- Central carbon metabolism in cancer
- Chemical carcinogenesis - receptor activation
- Choline metabolism in cancer
- Colorectal cancer
- Diabetic cardiomyopathy
- EGFR tyrosine kinase inhibitor resistance
- Endocrine resistance
- ErbB signaling pathway
- Gastric cancer
- Glioma
- Growth hormone synthesis, secretion and action
- HIF-1 signaling pathway
- Hepatocellular carcinoma
- Herpes simplex virus 1 infection
- Human cytomegalovirus infection
- Human immunodeficiency virus 1 infection
- Human papillomavirus infection
- Huntington disease
- Insulin resistance
- Insulin signaling pathway
- Integrin signaling
- JAK-STAT signaling pathway
- Kaposi sarcoma-associated herpesvirus infection
- Longevity regulating pathway
- Longevity regulating pathway - multiple species
- Lysosome biogenesis
- MicroRNAs in cancer
- Neutrophil extracellular trap formation
- PD-L1 expression and PD-1 checkpoint pathway in cancer
- PI3K-Akt signaling pathway
- Pancreatic cancer
- Pathways in cancer
- Pathways of neurodegeneration - multiple diseases
- Phospholipase D signaling pathway
- Prostate cancer
- Proteoglycans in cancer
- Shigellosis
- Spinocerebellar ataxia
- Th17 cell differentiation
- Thermogenesis
- Thyroid hormone signaling pathway
- Type II diabetes mellitus
- mTOR signaling pathway
Associated Diseases (2)
Active Molecules (2,517)
| InChIKey | pChEMBL | Type | Targets | Clinical | |
|---|---|---|---|---|---|
KXIQRMIPXPVUID
|
9.1 | IC50 | 3 | — | |
MEENXBJHESDXRJ
|
9.1 | IC50 | 3 | — | |
NHQOSODHGLNYEK
|
9.1 | IC50 | 2 | — | |
UQBDVXGNVUOMQH
|
9.1 | IC50 | 2 | — | |
YYIGVVUQYWUSKX
|
9.1 | IC50 | 2 | — | |
ZPRTUWGSRQNCTH
|
9.1 | IC50 | 2 | — | |
DBDFQJQWQAVATL
|
9.1 | Ki | 2 | — | |
FDFNMUHAWFSYOD
|
9.1 | IC50 | 2 | — | |
LFTBFBXWPUSAAX
|
9.1 | IC50 | 2 | — | |
SDAKRJNIGMBAAY
|
9.1 | IC50 | 2 | — | |
CTFYIRDIWNNKBH
|
9.1 | IC50 | 3 | — | |
FEHMSOXLBSZWRN
|
9.1 | IC50 | 2 | — | |
HLHOHTNONYACFD
|
9.1 | IC50 | 3 | — | |
SALYYPNKGWCXSL
|
9.1 | IC50 | 2 | — | |
YZAXUUNTFHQIHS
|
9.1 | IC50 | 3 | — | |
ARICVBDWIFNOOD
|
9.1 | Ki | 2 | — | |
UWJFLQXOGWCELX
|
9.1 | pIC50 | 2 | Yes | |
RTDGYXSFJCXDAM
|
9.1 | IC50 | 2 | — | |
RXPZDVPCYZMEAB
|
9.1 | IC50 | 2 | — | |
UVPHXYOQBIOXLJ
|
9.1 | IC50 | 2 | — | |
ARKRGLDVMPXTLI
|
9.1 | IC50 | 2 | — | |
CVMZRJQIEUQWJM
|
9.1 | IC50 | 5 | — | |
ITYGQBOCBCGBAV
|
9.1 | IC50 | 2 | — | |
LMXYZMNDIFPRCF
|
9.1 | IC50 | 5 | — | |
NCMPMDQMBRJTPI
|
9.1 | IC50 | 2 | — | |
QIXLGRGBODTYKP
|
9.1 | IC50 | 2 | — | |
UBDPYTQTRSKDCC
|
9.1 | IC50 | 2 | — | |
UOXOWFBZFQTLKZ
|
9.1 | IC50 | 3 | — | |
VFHPBAUTOKQYCD
|
9.1 | IC50 | 2 | — | |
ZUZKIBPSJJPLFM
|
9.1 | IC50 | 2 | — | |
BPKWXBSQPKUOLV
|
9.0 | IC50 | 2 | — | |
OTOIKFVTBJUTPZ
|
9.0 | IC50 | 3 | — | |
QHTLNGNWJJKUEG
|
9.0 | IC50 | 2 | — | |
HPFFUPAXSKPNNJ
|
9.0 | IC50 | 2 | — | |
RLZIWQDVHJTWEF
|
9.0 | IC50 | 2 | — | |
VSHOLVLSSFDEKC
|
9.0 | IC50 | 2 | — | |
DJTMJLSVEUKIGG
|
9.0 | IC50 | 2 | — | |
DAWFYIDODFGOFZ
|
9.0 | IC50 | 2 | — | |
AGUQPSPLYMXJEI
|
9.0 | IC50 | 2 | — | |
AIDMXXRYUDRZOV
|
9.0 | IC50 | 2 | — | |
AJJYRWYJJMMKIT
|
9.0 | IC50 | 5 | — | |
AQKWKBKPEQNWIP
|
9.0 | IC50 | 2 | — | |
BVHGPAUHGYTFMJ
|
9.0 | IC50 | 2 | — | |
CNNMZNARDXPHPB
|
9.0 | pIC50 | 2 | Yes | |
DBVXEDIWOSVHPX
|
9.0 | pIC50 | 2 | Yes | |
DFZZGJMXAGYQAS
|
9.0 | IC50 | 2 | — | |
FEJIEJMRLPNJMJ
|
9.0 | IC50 | 2 | — | |
HXANWSROTQADER
|
9.0 | IC50 | 2 | — | |
IDSGZHKCQBRAEY
|
9.0 | IC50 | 2 | — | |
IWGYKKQUKQZOMH
|
9.0 | IC50 | 5 | — |